Molecular Biology Program
The John Maciejowski Lab
Research
Associate Member
Cancer genomes are unstable. Chromosomes are mis-segregated, telomeres fail, and broken chromosomes fuse and break again. Each of these leaves DNA in the wrong place or the wrong state inside the cell, and the Maciejowski lab studies what follows.
One line of work concerns the immune consequences. DNA that escapes into the cytoplasm, at micronuclei and at chromosome bridges, is detected by the sensor cGAS and triggers an inflammatory response. The lab has shown that the exonuclease TREX1 degrades this DNA from the endoplasmic reticulum, that a protein barrier assembled around the exposed DNA governs access to it, and that tumors induce TREX1 to shield themselves from immune surveillance. Removing TREX1 restores antitumor immunity in tumors able to respond.
A second line concerns what instability writes into the genome. The lab studies APOBEC3A, a major source of point mutations in human cancer, and the rare, transient cell state that licenses its activity. It also studies extrachromosomal DNA, the circular elements that carry amplified oncogenes and are inherited through an active mechanism despite lacking centromeres.
The lab combines cell biology, biochemistry, and genomics. Full details of current research, people, publications, and openings are at maciejowskilab.org.
Research Projects
Featured News
Publications Highlights
People
John Maciejowski, PhD
Associate Member
- John Maciejowski studies how genomic instability shapes cancer. His lab works on how tumors keep the immune system from detecting their own displaced DNA, and on the patterns of mutation and oncogene amplification that instability writes into the cancer genome.
- PhD, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center
- [email protected]
- Email Address
Members
- PhD, Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center
- BA, Columbia University
- BS, City University of Hong Kong
- Cancer Biology
Achievements
- Cancer Immunology Research Award for Outstanding Journal Article (2026)
- Louise and Allston Boyer Young Investigator Award for Basic Research (2025)
- Pershing Square Sohn Cancer Research Alliance Prize (2023)
- Frank A. Howard Scholar (2022)
- Pew Biomedical Scholar (2019)
- V Foundation Scholar (2018)
- NIH Pathway to Independence Award (2016)
- Regeneron Prize for Creative Innovation (2016)
- Tri-Institutional Breakout Prize for Junior Investigators (2016)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Open Positions
Get in Touch
-
Lab Head Email
-
Lab Phone
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
John Maciejowski discloses the following relationships and financial interests:
-
MilliporeSigma
Intellectual Property Rights
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].